hyperglycemia in pregnancy
Conditions
Interventions
Drinking pre meal milk group:None
Not drinking pre meal milk group:None
Sponsors
The Second Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. 18 - 45 years old; 2. Patients diagnosed with hyperglycemia in pregnancy according to the ‘Guideline of diagnosis and treatment of hyperglycemia in pregnancy (2022) ’; 3. Volunteer to participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. History of disease: Individuals with autoimmune diseases, tumors, severe infections, severe liver or kidney dysfunction, hematologic disorders, severe cardiovascular or cerebrovascular diseases (such as myocardial infarction, heart failure, stroke, coronary artery bypass surgery, or angina), mental disorders, syphilis, HIV/AIDS, or other serious conditions; 2. Complications at the time of diagnosis: such as severe anemia or intrauterine growth restriction (IUGR), etc; 3. Medications that may interfere with OGTT: If the pregnant woman is taking medications that could interfere with glycemic test results (such as high-dose steroids, immunosuppressants, etc.) during the oral glucose tolerance test (OGTT).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| oral glucose tolerance test (OGTT);Fasting blood glucose;Incremental Area Under the Curve (iAUC);Coefficient of Variation (CV);Area under the curve (AUC);2-hour postprandial blood glucose;Standard deviation of blood glucose (SDBG);hemoglobin A1c (HbA1c);Glucose management indicator (GMI);Mean blood glucose (MG);Time in range (TIR);TIme below range (TBR); | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA2-ß;Mean amplitude of glycemic excursions (MAGE);Largest amplitude of glycemic excursions (LAGE);Disposition index (DI);Mean of daily differences (MODD);Adverse neonatal outcomes;HOMA-ß;Continuous overlapping net glycemic action - n (CONGA-n);Maternal adverse outcomes;Time above range (TAR);Fasting C-peptide (FCP);Fasting insulin (FINS); | — |
Countries
China
Contacts
Public ContactFang Wang
The Second Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed